SkinBioTherapeutics (LON:SBTX) Stock Price Up 6.5% – Time to Buy?
by Teresa Graham · The Cerbat GemSkinBioTherapeutics plc (LON:SBTX – Get Free Report)’s share price traded up 6.5% during mid-day trading on Monday . The stock traded as high as GBX 16 and last traded at GBX 15.18. 1,832,994 shares changed hands during trading, an increase of 56% from the average session volume of 1,175,881 shares. The stock had previously closed at GBX 14.25.
SkinBioTherapeutics Stock Up 6.5%
The stock has a market capitalization of £39.27 million, a P/E ratio of -12.14 and a beta of 2.01. The stock’s fifty day simple moving average is GBX 15.24 and its two-hundred day simple moving average is GBX 15.56. The company has a debt-to-equity ratio of 27.57, a quick ratio of 10.01 and a current ratio of 0.93.
SkinBioTherapeutics (LON:SBTX – Get Free Report) last released its quarterly earnings results on Monday, December 8th. The company reported GBX (0.31) earnings per share (EPS) for the quarter. SkinBioTherapeutics had a negative return on equity of 115.86% and a negative net margin of 237.95%.
About SkinBioTherapeutics
SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.